{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-23-011755","form_type":"8-K","ticker":"PGEN","cik":"0001356090","company_name":"PRECIGEN, INC.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.690762+00:00","generated_at":"2026-06-11T21:38:51.995617+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FDA confirms PRGN-2012 Phase 1/2 study as pivotal for accelerated approval; cash runway into 2025","bullets":["FDA confirmed ongoing Phase 1/2 single-arm study of PRGN-2012 for RRP as pivotal for accelerated approval; no placebo trial needed.","Retired all outstanding convertible notes in Q2; cash, equivalents, and investments totaled $95.6M as of June 30, 2023.","Q2 2023 loss from continuing operations was $20.3M ($0.08/share), improved from $26.1M loss in Q2 2022.","SG&A expenses decreased 27% Q2 vs prior year; revenue fell 39% due to reduced services at Exemplar.","Projected cash runway into 2025; Phase 2 enrollment complete, data collection by Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-23-011755","json":"https://secwatch.observer/filing/0000950103-23-011755.json","markdown":"https://secwatch.observer/filing/0000950103-23-011755.md","text":"https://secwatch.observer/filing/0000950103-23-011755.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356090/000095010323011755/0000950103-23-011755-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356090/000095010323011755/dp198223_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:38:51.995617+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ea4c3c21584d6013922a34e5b6f7a5f80bf3cce","claim":"PRECIGEN, INC. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated August 9, 2023, reporting its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356090/000095010323011755/0000950103-23-011755-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}